Oncology Pharma Inc.
20.7.2021 13:32:38 CEST | ACCESS Newswire | Press release
SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is laying out and taking necessary steps to move its licensed IP forward. From obtaining the necessary financing, in order to support studies, to obtaining the data utilizing mouse or rat clinical trials ("Mouse clinical trials" or "MCT") all steps are being established. The Company has decided to pursue moving forward with MCT as it most closely represents the setting of a human clinical trial.
Human preclinical methods are different as they use a small number of models with a large number of tests per subject. Mouse clinical trials tend to upend the traditional preclinical paradigm and better resemble and match the actual clinical setting. The Company believes this is an effective and cost-efficient way of moving forward. Utilizing MCTs will develop data that can be leveraged for biomarker discovery, which is ever more crucial for clinical trial success.
In addition, the Company continues to develop its business model to support the currently licensed IP and providing them with the necessary tools each individual licensor needs to support their individual business so they can contribute to the business plan of Oncology Pharma, Inc.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
Website: www.oncology-pharma.com
Email: info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/656221/Oncology-Pharma-Inc-To-Move-to-Conducting-Trials-on-Licensed-IP
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
DocStyle Announces DocStyle AI: Document Productivity Tools, Accessible from the AI Assistants Lawyers Already Use19.8.2026 16:00:00 CEST | Press release
The new solution connects DocStyle's document engine to Claude for Word, Microsoft Copilot, and a dedicated chat pane, available for pre-order today ahead of general availability on October 1st. MIAMI, FL / ACCESS Newswire / August 19, 2026 / DocStyle, a leading provider of legal document repair, structuring, and automation solutions, today announced DocStyle AI. Rather than embedding a general AI chat into its software, DocStyle made its full document productivity engine accessible from the AI assistants legal professionals already use, including Claude for Word and Microsoft Copilot, alongside a dedicated DocStyle AI chat pane inside the DocStyle Ribbon. Built on the Model Context Protocol (MCP), an open standard, DocStyle AI is vendor-independent by design, staying reachable as AI models change and protecting the customer's investment. "We have always known that when making substantive changes to Word documents, you have to be inside Microsoft Word," said Chris Cangero, CEO of DocSt
Europe SPAC Summit 2026 to Convene Leading SPAC Sponsors, Investors, and European Growth Companies in Zurich on December 1019.8.2026 15:00:00 CEST | Press release
One-Day, Invitation-Only Summit Maps the Path from European Innovation to U.S. Capital Markets NEW YORK, NY AND ZURICH, SWITZERLAND / ACCESS Newswire / August 19, 2026 / As a landmark year for European companies in the U.S. public markets continues to build momentum, the Europe SPAC Summit will convene the dealmakers driving the region's de-SPAC renaissance, turning its focus to deal flow, capital formation, and every stage of the path from European innovation to a thriving U.S. listing. The invitation-only Summit takes place on Thursday, December 10, 2026, at The Dolder Grand in Zurich, Switzerland, co-hosted by AUM Advisors and MBP Global. The Summit features a keynote session with Kyivstar, Ukraine's largest mobile operator, whose successful Nasdaq listing through a merger with a SPAC sponsored by Cohen Circle, the investment platform founded by fintech pioneer Betsy Cohen, demonstrates that this approach can create real value for Europe's growth companies. The program also includes
SMBs Attract Talent with AI Upskilling as Large Firms Cut Jobs and Benefits, Study Finds18.8.2026 12:00:00 CEST | Press release
General Assembly study finds role-specific AI training is the most effective approach for SMBs NEW YORK CITY, NY / ACCESS Newswire / August 18, 2026 / Small-to-medium employers (SMBs) see their human talent as a key area of investment for the AI era and are seeing strong impact from role-specific AI training, according to new research from General Assembly, a global leader in practical AI skills training. Layoff and benefit reductions at larger companies have made it easier for SMBs to recruit and retain top talent, say 81% of human resources (HR) leaders at SMBs, while nearly half (47%) of SMBs have already hired from larger firms in the past year. "Growth-stage companies see AI adoption as a catalyst, not a cost-cutting exercise," said Daniele Grassi, CEO of General Assembly. "They're able to move faster to implement AI and scale it quickly, and they're upskilling their workforces accordingly. As talent sees daily headlines around layoffs and benefit reductions, they're increasingly
LiberNovo Previews Support Week 2026, Putting Better Ergonomic Support Within Reach18.8.2026 10:00:00 CEST | Press release
Support Week starts August 25. We've got your back. HONG KONG, HK / ACCESS Newswire / August 18, 2026 / One size does not fit all. Yet most ergonomic chairs are still built around a standard frame, leaving taller, broader, and heavier users adapting to the chair instead of the chair adapting to them. LiberNovo is addressing that gap with the Maxis Series, the lead range for LiberNovo Support Week 2026, opening August 25 across the European Union and United Kingdom. Built for Bigger Builds Maxis was engineered at full scale, not adapted from a standard chair platform. A 52 cm seat depth provides greater thigh support, while a wider seat cushion gives users more room to shift naturally. Its reinforced frame supports up to 181 kg. Maxis also features a five-stage recline control system from 105° to 160°, supported by a Segmented Support System using progressive springs. This provides controlled, consistent support throughout the recline range, even under heavier loads. Three configuration
IFS Softeon Announces Successful First Go-Live with BF Global Group in Europe13.8.2026 14:00:00 CEST | Press release
First deployment marks a major milestone in strategic multi-site warehouse modernisation initiative. RESTON, VA / ACCESS Newswire / August 13, 2026 / IFS Softeon, the warehouse management system (WMS) provider delivering visibility from the boardroom to the warehouse floor, today announced the successful go-live of its warehouse management system at the first BF Global Group distribution centre, marking a significant milestone in the companies' strategic partnership announced earlier this year. The first deployment supports a leading premium stroller and baby products brand and represents the initial phase of BF Global Group's broader rollout of IFS Softeon Warehouse Management System across facilities throughout Europe in partnership with Lanark. The implementation was completed through a carefully coordinated weekend cutover, with operations transitioning successfully to the new platform. Since go-live, the facility has successfully processed and shipped both B2B and B2C customer ord
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom